Discovery engine for small molecule modulators of disordered targets
Our science
Nuage Therapeutics mission is to leverage chemical biology and biomolecular condensation to develop selective drugs targeting proteins with disordered regions for challenging indications to improve patient’s life
Our team
Xavier Salvatella
Founder
Mateusz Biesaga
Founder
Denes Hnisz
Founder
Judit Anido
Founder & CEO
Pilar Casado
Chief Financial Officer
Jordina Guillén
Head of Science
Andri Leonidou
Head of BI & Corp. Affairs
Alessandra Bartolozzi
Head of Medicinal Chemistry
Board of Directors
Clara Campàs
Board member
Xavier Salvatella
Board member
Maina Bhaman
Board member
Judit Anido
Board member
Nuage Therapeutics scientific founders publish new research in Nature Structural & Molecular Biology
December 4, 2023
Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys
June 21, 2023
Nuage Therapeutics appoints biotech entrepreneur and executive Judit Anido as CEO
May 10, 2022
Nuage Therapeutics, the spin-off from IRB Barcelona and ICREA is launched with the support of Asabys
September 28, 2021
Private investors:
This company is invested by Innvierte, an investment program of CDTI, E.P.E.
Project grants:
- Nuage Therapeutics has been awarded with the CDTI grant SNEO-2022214, in collaboration with Ministerio de Ciencia e Innovación and cofunded by the European Union–Next Generation EU
- Grant PTQ2021-011994 and PTQ2021-011961 awarded by MCIN/AEI/10.13039/501100011033
Careers
Job opening for Business Development Manager at Nuage Therapeutics
view details
Job opening for Scientist (assay development) at Nuage Therapeutics
view details
Get in touch
Xavier Salvatella
Founder
ICREA Professor, Leader of the Laboratory of Molecular Biophysics at IRB Barcelona. Expert in intrinsically disordered proteins, biomolecular condensation and the structural and functional properties of the transactivation domain of androgen receptor.
Maina Bhaman
Partner, Sofinnova Partners Capital Strategy
Maina joined Sofinnova as a partner in 2018 and serves on the boards of directors of Sitryx Therapeutics, Cincor and Enyo Pharma. Previously, she was director of healthcare investment at Touchstone Innovations (formerly Imperial Innovations) in London and worked in the R&D teams of several U.K. and U.S. biotech companies, including Celltech, Oxford GlycoSciences, Chimeric Therapies and GeneMedicine.
Maina holds a B.S. from the University of Texas at Austin and an MBA from the Imperial Business School.
Mateusz Biesaga
Founder
Biomedical engineer with a PhD in Biomedicine specialised in biophysics and assay development for drug discovery. Led initial development and validation of Nuage’s HTS platform for identifying modulators of intrinsically disordered proteins during his MSCA fellowship at IRB Barcelona.
Denes Hnisz
Founder
Leader of the Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin. Expert in transcriptional control, nuclear condensates and genome structure. Has served as a consultant with startup biotechnology companies in the Boston area.
Georgina Sorrosal
Head of Operations
Biotechnologist with a PhD in Genetics and a Developmental Biology research background. Expertise in science management for 11 years, including venture capital in the healthcare sector, knowledge transfer and innovation in a hospital environment & project management in both public and private biopharma sectors.
Jordina Guillén
Head of Science
Biologist with a PhD in Molecular Biology and 10 years of experience in biomedical research. Expertise in intrinsically disordered proteins, biomolecular condensates and gene expression regulation.
Clara Campàs
Chair
Pilar Casado
Chief Financial Officer
Judit Anido
Founder & CEO
Seasoned biotech entrepreneur and executive. Formerly, Co-founder and CEO of Mosaic Biomedicals, a biotech company developing innovative drugs for cancer treatment. After the merger with the Canadian Northern Biologics, also became Vice-President of Operations and Corporate Affairs at Northern. The assets of the companies were acquired by Boehringer Ingelheim and AstraZeneca.
Judit also served as CEO and President of CataloniaBio & HealthTech, the Catalan association of companies in the health sector. Holds a PhD in Biology from the University of Barcelona and an MBA from Duke University (US).
Andri Leonidou
Head of BI & Corp. Affairs
Life sciences business professional with 4+ years of experience in the pharmaceutical industry and 10+ years of experience in oncology research and drug discovery. Expertise in competitive intelligence, business strategy, and market dynamics.
Andri holds a PhD in Oncology from the Institute of Cancer Research, University of London, and is working towards an Executive MBA.
Alessandra Bartolozzi
Head of Medicinal Chemistry
Alessandra brings over 20 years of experience in drug discovery during which she enabled project strategies across multiple target classes and therapeutic areas. The projects she has led have encompassed all stages of the discovery process, ranging from hit-identification to pre-clinical development candidate selection.
Prior to Nuage Therapeutics, Alessandra worked in both small and large pharma, including Boehringer Ingelheim where she had several roles including Senior Associate Director of Medicinal Chemistry, and Senda Biosciences where she was the Head of Chemistry. Alessandra completed her PhD in Organic Chemistry at the University of Florence, Italy, followed by a postdoctoral appointment in the Department of Chemistry at MIT. Alessandra is an inventor on over 25 patents and patent applications and has published over 20 articles in peer-reviewed journals.